Related Experiment Video
Updated: Jan 23, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
Andreas H Groll1, Bart J A Rijnders2, Thomas J Walsh3
1Infectious Disease Research Program, Department of Pediatric Hematology and Oncology and Center for Bone Marrow Transplantation, University Children's Hospital Muenster, Germany.
Abstract:
Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an important agent for the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds. This liposomal formulation was developed to improve the tolerability of intravenous amphotericin B, while optimizing its clinical efficacy. Since then, numerous clinical studies have been conducted, collecting a comprehensive body of evidence on its efficacy, safety, and tolerability in the preclinical and clinical setting. Nevertheless, insights into the pharmacokinetics and pharmacodynamics of LAmB continue to evolve and can be utilized to develop strategies that optimize efficacy while maintaining the compound's safety. In this article, we review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB in a wide variety of patient populations and in different indications, and provide an assessment of areas with a need for further clinical research.
Insights
Liposomal amphotericin B (LAmB) remains crucial for invasive fungal infections. This review details its pharmacokinetics, pharmacodynamics, safety, and efficacy, highlighting areas for future research to optimize treatment.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Liposomal amphotericin B (LAmB) is a key antifungal medication introduced in the 1990s.
- It was developed to enhance the tolerability and efficacy of intravenous amphotericin B.
- Extensive preclinical and clinical data support its use in treating invasive fungal infections.
Purpose of the Study:
- To review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB.
- To assess LAmB's performance across diverse patient populations and indications.
- To identify areas requiring further clinical investigation for LAmB optimization.
Main Methods:
- Comprehensive literature review of clinical studies on LAmB.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Evaluation of safety and efficacy profiles in various patient groups.
Main Results:
- LAmB demonstrates established efficacy and safety in treating invasive fungal diseases.
- Evolving pharmacokinetic and pharmacodynamic insights offer opportunities for treatment optimization.
- Evidence supports LAmB's role in managing infections caused by yeasts and molds.
Conclusions:
- LAmB is an important agent for invasive fungal diseases, with a well-documented profile.
- Further research into LAmB's pharmacokinetics and pharmacodynamics can refine treatment strategies.
- Optimizing LAmB use requires continued clinical investigation to balance efficacy and safety.
Related Concept Videos
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Survey Safety
Measurement of Bioavailability: Pharmacodynamic Methods
Self-Efficacy
Pharmacodynamics in Geriatric Patients: Effects of Age
Household Wiring And Electrical Safety

